Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience

Patrizia Ciammella, Ala Podgornii, Maria Galeandro, Nunziata D'Abbiero, Anna Pisanello, Andrea Botti, Elisabetta Cagni, Mauro Iori, Cinzia Iotti, Patrizia Ciammella, Ala Podgornii, Maria Galeandro, Nunziata D'Abbiero, Anna Pisanello, Andrea Botti, Elisabetta Cagni, Mauro Iori, Cinzia Iotti

Abstract

Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists.

Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.

Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption.

Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis of overall survival from the time of initial diagnosis in patients with recurrent GBM treated with radiotherapy (RT), surgery (Sur), chemotherapy (CT) or best supportive care.
Figure 2
Figure 2
Kaplan-Meier analysis of overall survival from the time of recurrence in patients with recurrent GBM treated with radiotherapy (RT), surgery (Sur), chemotherapy (CT) or best supportive care.

References

    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330.
    1. van den Bent MJ, Brandes AA, Rampling R. et al.Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurret glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol. 2009;27(8):1268–1274. doi: 10.1200/JCO.2008.17.5984.
    1. Brandes AA, Tosoni A, Amista P. et al.How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63(7):1281–1284. doi: 10.1212/.
    1. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO. et al.BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factord. BMC Cancer. 2010 Feb 2;10:30. doi: 10.1186/1471-2407-10-30.
    1. Batchelor T, Mulholland P, Neyns B. et al.The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized trial. Neuro Oncol. 2010;12(Suppl. 4):75.
    1. Happold C, Roth P, Wick W. et al.ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol. 2009;92(1):45–48. doi: 10.1007/s11060-008-9728-9.
    1. Addeo R, Caraglia M, De Santi MS. et al.A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neuroncol. 2011;102(3):417–424. doi: 10.1007/s11060-010-0329-z.
    1. Scoccianti S, Detti B, Sardaro A. et al.Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs. 2008;19(6):613–620. doi: 10.1097/CAD.0b013e3283005075.
    1. Brada M, Hoang-Xuan K, Rampling R. et al.Randomized phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;1282:259–266.
    1. Brandes AA, Ermani M, Basso U. et al.Temozolomide as a second-line sistemi regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2011;12(2):255–257.
    1. Brandes AA, Ermani M, Basso U. et al.Temozolomide in patients with glioblastoma at second relapse after first line nitrosurea-procarbazine failure: a phase II study. Oncology. 2002;63(1):38–41. doi: 10.1159/000065718.
    1. Khan RB, Raizer JJ, Malkin MG. et al.A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002;4(1):39–43.
    1. Brandes AA, Tosoni A, Cavallo G. et al.Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO) Br J Cancer. 2006;95(9):1155–1160. doi: 10.1038/sj.bjc.6603376.
    1. Balmaceda C, Peereboom D, Pannullo S. et al.Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112(5):1139–1146. doi: 10.1002/cncr.23167.
    1. Wick W, Steinbach JP, Kuker WM. et al.One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62(11):2113–2115. doi: 10.1212/01.WNL.0000127617.89363.84.
    1. Yung WK, Albright RE, Olson J. et al.A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–593. doi: 10.1054/bjoc.2000.1316.
    1. Franceschi E, Omuro AM, Lassman AB, Demopoulos A. et al.Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104(11):2473–2476. doi: 10.1002/cncr.21564.
    1. Kong DS, Lee JI, Kim WS. et al.A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16(5):117–1121.
    1. Berrocal A, Perez Segura P, Gil M. et al.Extended-schedule dose-dense temozolomide in refractory gliomas. J Neuroncol. 2010;96(3):417–422. doi: 10.1007/s11060-009-9980-7.
    1. Kong DS, Lee JI, Kim JH. et al.Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010;12(3):289–296. doi: 10.1093/neuonc/nop030.
    1. Hammond A, Norden AD, Lesser GJ. et al.Phase II study of dose-intense temozolomide in recurrent gliblastoma. J Clin Oncol. 2038;2011:29.
    1. Park JK, Hodges T, Arko L. et al.Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838–3843. doi: 10.1200/JCO.2010.30.0582.
    1. Barbagallo GM, Jenkinson MD, Brodbelt AR. Recurrent Gliobastoma multiforme- when should we reoperate? Br J Neurosurg. 2008;22(3):452–455. doi: 10.1080/02688690802182256.
    1. Dhermain F, de Crevoisier R, Parker F, Cioloca C, Kaliski A, Beaudre A, Lefkopoulos D, Armand JP, Haie-Meder C. Role of radiotherapy in recurrent gliomas. Bull Cancer. 2004;91(11):883–889.
    1. Coombs SE, Debus J, Shulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167. doi: 10.1186/1471-2407-7-167.
    1. Hall WA, Djalilian HR, Sperduto PW. et al.Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol. 1995;13:1642–1648.
    1. Cabrera AR, Cuneo KC, Vredenburgh JJ. et al.Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw. 2012 Jun 1;10(6):695–699.
    1. Combs SE, Widmer V, Thilmann C. et al.Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM) Cancer. 2005;104:2168–2173. doi: 10.1002/cncr.21429.
    1. Patel M, Siddiqui F, Jin JY, Mikkelsen T. et al.Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009;92:185–191. doi: 10.1007/s11060-008-9752-9.
    1. Cho KH, Hall WA, Gerbi BJ, Higgins PD. et al.Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;45:1133–1141. doi: 10.1016/S0360-3016(99)00336-3.
    1. Combs SE, Gutwein S, Thilman CH. et al.Stereotactically guided fractionated reirradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167–171. doi: 10.1007/s11060-004-2463-y.
    1. Combs SE, Thilman CH, Edler L. et al.Efficacy of fractionated stereotactic reiraddiation in recurrent gliomas: long-term result in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–8869. doi: 10.1200/JCO.2005.03.4157.
    1. Vordermark D, Kolbl O, Ruprecht K. et al.Hypofractionated stereotactic re-irradiarion: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55. doi: 10.1186/1471-2407-5-55.
    1. Lederman G, Wronski M, Arbit E. et al.Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000;23:155–159. doi: 10.1097/00000421-200004000-00010.
    1. Arcicasa M, Roncadin M, Bidoli E. et al.Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;43:789–793. doi: 10.1016/S0360-3016(98)00457-X.
    1. Combs SE, Bischof M, Welzel T. et al.Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol. 2008;89:205–210. doi: 10.1007/s11060-008-9607-4.
    1. Minniti G, Armosini V, Salvati M. et al.Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol. 2011;103(3):683–691. doi: 10.1007/s11060-010-0446-8.
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. IARC: Lyon; 2007.
    1. Lee SW, Fraas BA, Marsh LH. et al.Patterns of failure following hig-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43(199):79–88.
    1. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21:607–614. doi: 10.1227/00006123-198711000-00001.
    1. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurgical focus. 2006;20:E5.
    1. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000;26:397–409. doi: 10.1053/ctrv.2000.0191.
    1. Stupp R, Hegi ME, Gilbert MR. et al.Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127–4136. doi: 10.1200/JCO.2007.11.8554.
    1. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R. et al.O(6)-methylguanine DNA-methyltransferase methyleation status can change between first surgery for newly diagnosed glioblastoma and second surgery from recurrence: clinical implications. Neuro Oncol. 2010;12:283–288. doi: 10.1093/neuonc/nop050.
    1. Vredenburgh JJ, Desjardinis A, Herndon JE 2nd. et al.Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729. doi: 10.1200/JCO.2007.12.2440.
    1. Young B, Oldfield EH, Markesbery WR, Haack D, Tibbs P, McCoombs P. et al.Reoperation for glioblastoma. J Neurosurg. 1981;55:917–921. doi: 10.3171/jns.1981.55.6.0917.
    1. Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD. et al.Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42:709–720. doi: 10.1097/00006123-199804000-00013.
    1. Sirin S, Oysul K, Surenkok S. et al.Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: a single center experience. Vojnosanit Pregl. 2011;68(11):961–6. doi: 10.2298/VSP1111961S.
    1. Simon JM, Cornu P, Boisserie G. et al.Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys. 2002;53:67–74. doi: 10.1016/S0360-3016(01)02804-8.
    1. Chan TA, Weingart JD, Parisi M. et al.Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:1133–1139. doi: 10.1016/j.ijrobp.2004.12.032.
    1. Larson DA, Prados M, Lamborn KR. et al.Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002;54:1397–1404. doi: 10.1016/S0360-3016(02)03743-4.
    1. Shrieve DC, Alexander E 3rd, Wen PY. et al.Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36:275–282. doi: 10.1227/00006123-199502000-00006. discussion 282–4.
    1. Grosu AL, Weber WA, Franz M. et al.Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–519. doi: 10.1016/j.ijrobp.2005.01.056.
    1. Kohshi K, Yamamoto H, Nakahara A. et al.Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol. 2007;82:297–303. doi: 10.1007/s11060-006-9283-1.
    1. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007;81:287–294. doi: 10.1007/s11060-006-9231-0.
    1. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol. 2009;185:235–240. doi: 10.1007/s00066-009-1753-x.
    1. Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C. Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol. 2009;185:113–119. doi: 10.1007/s00066-009-1969-9.
    1. Fogh SE, Anrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28:3048–3053. doi: 10.1200/JCO.2009.25.6941.
    1. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393–398. doi: 10.1016/S0360-3016(96)00455-5.
    1. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive or persistent malignant astrocytoma. Am J Clin Oncol. 1997;20:226–229. doi: 10.1097/00000421-199706000-00002.
    1. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:291–298.
    1. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002;25:606–611. doi: 10.1097/00000421-200212000-00017.
    1. Veninga T, Langendijk HA, Slotman BJ. et al.Reirradiation of primary brain tumors: serviva, clinical response and prognostic factors. Rdaiother Oncol. 2001;59:127–137. doi: 10.1016/S0167-8140(01)00299-7.
    1. Nieder C, Astner ST, Mehta MP. et al.Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol. 2008;31:300–305. doi: 10.1097/COC.0b013e31815e3fdc.
    1. Chang EL, Akurek S, Avalos T. et al.Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys. 2007;86:144–150.
    1. Liang BC, Thornton AF Jr, Sandler HM. et al.Malignant atrocytomas: focal tumor recurrence after local external beam radiation therapy. J Neurosurg. 1991;75:559–563. doi: 10.3171/jns.1991.75.4.0559.
    1. Lee SW, Fraass BA, Marsh LH. et al.Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43:79–88. doi: 10.1016/S0360-3016(98)00266-1.
    1. McDonald MW, Shu HK, Curran WJ. et al.Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79:130–136. doi: 10.1016/j.ijrobp.2009.10.048.
    1. Minniti G, Amelio D, Amichetti M. et al.Patterns of failure and comparison of different target volume delineations in patients with gliobalstoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Rdaiother Oncol. 2010;97:377–381. doi: 10.1016/j.radonc.2010.08.020.
    1. Milano MT, Okunieff P, Donatello RS. et al.Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78:1147–1155. doi: 10.1016/j.ijrobp.2009.09.018.
    1. Brandes AA, Tosoni A, Franceschi E. et al.Recurrence pattern after temozolomide concomitant with and ajuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27:1275–1279. doi: 10.1200/JCO.2008.19.4969.
    1. Hochberg FH, Pruitt A. Assumption in the radiotherapy glioblastoma. Neurology. 1980;30:907–911. doi: 10.1212/WNL.30.9.907.
    1. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018.
    1. Laing RW, Warrington AP, Graham J. et al.Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (Phase I/II study) Radiother Oncol. 1993;27:22–29. doi: 10.1016/0167-8140(93)90040-F.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit